Preclinical Evaluation of New Taxoids

Author: Bissery, M.

Source: Current Pharmaceutical Design, Volume 7, Number 13, 1 September 2001 , pp. 1251-1257(7)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

Paclitaxel and docetaxel are two key molecules in the treatment of a variety of cancers with major impact in the treatment of breast, lung and ovarian cancers.

A number of taxoids have then been synthesized in an effort to improve some of the features of the existing drugs. Although the literature is still scant of preclinical data due to the highly competitive field, several compounds are already in clinical trials. Most of these will be reviewed and have, either improved water solubility or reduced cross-resistance with marketed taxoids or reduced interaction with P-glycoprotein.

In addition, the reduced recognition of several compounds by multi-drug-resistance-related transport systems has yielded some orally bioavailable compounds with marked in vivo antitumor activity.

It is likely that these additional properties should lead to an expanded spectrum of clinical activity compared to that of clinically available taxoids.

Keywords: Taxoids; Cytotoxicity; Taxus; TXD258; RPR 109881A; BMS 185660; BMS 188797; BMS 184476

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1381612013397465

Publication date: 2001-09-01

More about this publication?

Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.